Anna Bucsics

Anna Bucsics

Auto-generated profile, based on publicly available information

Anna Bucsics

MoCA, Mechanism of Coordinated Access to Orphan Medicinal Products, Austria, Vienna

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YTYuxi Tian
Yuxi Tian
BRBerthold Reichardt
Berthold Reichardt
DDDaniela Dunkler
Daniela Dunkler
MHMilan Hronsky
Milan Hronsky
WWWolfgang C. Winkelmayer
Wolfgang C. Winkelmayer
Georg HeinzeGeorg Heinze
Georg Heinze
Generic medications offer substantial potential cost savings to health systems compared to their branded counterparts. In Europe and the US, they are only approved if they are bioequivalent to the respective originator product. Nevertheless, the lack of clinical outcomes is sometimes used as the reason for hesitancy in prescribing generics. We performed an observational retrospective study on 17 branded vs. generic pharmaceutical substances for the treatment of hypertension/heart failure, hyperlipidemia, and diabetes mellitus in a dataset of 9,413,620 insured persons, representing nearly the full population of Austria, from 2007 to 2012. We compared generic vs. branded medications using hazard ratios for all-cause death and major adverse cardiac and cardiovascular events (MACCE) as outcomes of interest. Using patient demographics, health characteristics from hospitalization records, and pharmacy records as covariates, we controlled for confounding in Cox models through inverse probability of treatment weighting (IPTW) using high-dimensional propensity scores. We observed that the unadjusted hazard ratios strongly favor generic drugs for all three pooled treatment indications (hypertension/heart failure, hyperlipidemia, diabetes mellitus), but were attenuated towards unity with increasingly larger covariate sets used for confounding control. We found that after IPTW adjustment the generic formulation was associated with significantly fewer deaths in 10 of 17 investigated drugs, and with fewer MACCE in 11 of 17 investigated drugs. This result favoring generic drugs was also present in a number of sub-analyses based on gender, prior disease status, and treatment discontinuation. E-value sensitivity analyses suggested that only strong unmeasured confounding could fully explain away the observed results. In conclusion, generic medications were at least similar, and in some cases superior, to their branded counterparts regarding mortality and major cardiovascular events.

1 May 2015 in Health Policy
Verified
Journal Article
Open access
SKSarah Kleijnen
Sarah Kleijnen
WTWil Toenders
Wil Toenders
FGFolkert de Groot
Folkert de Groot
MHMirjana Huic
Mirjana Huic
EGElisabeth George
Elisabeth George
WGWim Goettsch
Wim Goettsch
The objective of this study is to identify the possible barriers and critical success factors for the implementation of European collaboration in the field of relative effectiveness assessment (REA) of drugs. Data were gathered through semi-structured interviews with representatives from eight European health technology assessment (HTA) organisations involved in assessment of drugs for coverage decision-making (AAZ, AIFA, AHTAPol, HAS, HVB, IQWIG, NICE and ZiN). Potential barriers identified mainly relate to methodology, resources and challenges with implementation in the respective national processes (e.g. legal restrictions). The most critical success factors for production of cross-border assessments were the continuous cooperation of competent partners, and the quality and timely availability of the assessment. Further adaptation of the process and methods is required for optimal collaboration. In the near future it can be expected that cross-border assessments will meet in particular the needs of smaller/middle-sized European countries and also European countries with less developed HTA systems as the potential efficiency/quality gains are the highest for these countries. Therefore, national implementation of cross-border assessments is especially likely in these countries in the coming years. Once more experience is gained with cross-border assessments, and successes become more evident, efficiency/quality gains may also be likely for some larger countries with well established processes.

1 February 2010 in Wiener klinische Wochenschrift
Verified
Journal Article
Closed access
PDF file
WWWolfgang C. Winkelmayer
Wolfgang C. Winkelmayer
MAMarkus Asslaber
Markus Asslaber
ABAnna Bucsics
Anna Bucsics
TBThomas Burkhardt
Thomas Burkhardt
ASAlexandra Schautzer
Alexandra Schautzer
MBM. Alan Brookhart
M. Alan Brookhart